Diet Drug Lorcaserin May Be A Cancer Risk


Health Editor’s Note: While there is no clear, conclusive evidence that Lorcaserin does increase a risk for cancer, in a large patient trial, those who took this weight management drug, ended up with an increase in cancer diagnoses  when compared to the group who did not take the drug. While the trial (five year) was designed to investigate the possibility that the drug might cause issues with heart valves, it was found to not be cardiotoxic, but the additional findings of increased cancer diagnoses is very concerning …..Carol

Diet Drug Possibly Linked to Cancer, FDA Says

by Crystal Phend/Senior Editor MedPage Today

Post-marketing study data on the weight management drug lorcaserin (Belviq, Belviq XR) showed an increase in cancer risk, the FDA cautioned.

The drug safety communication warned that the mechanism isn’t clear and it’s not certain that the link is causal. Moreover, the announcement didn’t quantify the increased risk. The agency’s review is still underway as it continues to evaluate clinical trial results.


Lorcaserin was approved in 2012 — as an adjunct to diet and exercise for those with a BMI of 30 or more, or a BMI of 27 with obesity-related comorbidities — after a rocky start with the FDA. Its first application was rejected by the FDA over a need for more safety data. The second time around, the FDA advisory panel was concerned about lack of data to rule out heart valve issues.

However, the CAMELLIA-TIMI-61 post-marketing trial specifically powered to look at cardiovascular outcomes with 5 years of lorcaserin use turned up no excess major adverse cardiovascular event risk and even a reduced risk of new-onset type 2 diabetes among those with prediabetes at baseline.

While cancer risk was not initially noted as an issue in that approximately 12,000-patient trial, FDA said that is where it noted the excess of patients diagnosed with cancer compared with the placebo group.

Some rat studies had suggested “mammary gland tumors in both sexes at clinically relevant exposures” and other tumor types in male rats at higher doses, according to an FDA review document from 2012. But “[o]verall, malignancies were seen infrequently in the Phase 3 program. No formal cancer screening was conducted,” it said, and the advisory committee “in general agreed that there is a sufficient safety margin for the drug when it is used at the concentrations intended for patients.”

Carol graduated from Riverside White Cross School of Nursing in Columbus, Ohio and received her diploma as a registered nurse. She attended Bowling Green State University where she received a Bachelor of Arts Degree in History and Literature. She attended the University of Toledo, College of Nursing, and received a Master’s of Nursing Science Degree as an Educator.

She has traveled extensively, is a photographer, and writes on medical issues. Carol has three children RJ, Katherine, and Stephen – two daughters-in-law; Suzy and Katie – two granddaughters; Isabella Marianna and Zoe Olivia – and one grandson, Alexander Paul. She also shares her life with husband Gordon Duff, many cats, and two rescue pups.

Carol’s Archives 2009-2013
DISCLOSURES: All content herein is owned by author exclusively.  Expressed opinions are NOT necessarily the views of VT, authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.

About VT - Read Full Policy Notice - Comment Policy


  1. That’s ok, the company will find a different use for it, relabel it as something else and make a ton of money from it, which will be used to bribe,er, donate to politicians for re-election.
    Oh, and to make “gifts to the FDA and CDC.

Comments are closed.